Y13g is a potent inhibitor of acetylcholinesterase (AChE) and interleukin-6 (IL-6), two key targets involved in the progression of Alzheimer's disease (AD); it reverses memory deficits induced by streptozotocin (STZ) and exhibits histopathological profiles similar to those of normal animals.